



# ESMO Congress Highlights Summary

## GI Tumors - Highlights



BARCELONA SPAIN  
13-17 SEPTEMBER 2024



13.09.2024

<b>Educational Session - Sevilla Auditorium - Hall 2</b>	
14:00 - 15:30	Metastatic colorectal cancer: Changing paradigms and the relevance for patient care
<b>Type: Industry Satellite Symposium - BMS - Santander Auditorium - Hall 5</b> Therapeutic Advances in GI Cancers: ImmunoOncology and Beyond	
10:20 - 10:47	Colorectal Cancer: Novel Combination Therapies S. Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
10:47 - 11:14	Gastroesophageal Cancers: the Role of Immunotherapy T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES
11:14 - 11:41	Hepatocellular Carcinoma: First-line Treatment Options in the Metastatic Setting T. Decaens, CHU Grenoble-Alpes - Le site nord à La Tronche - Hôpital Michallon, La Tronche, FR
<b>Type: Industry Satellite Symposium - BMS - Santander Auditorium - Hall 5</b> Pioneering GI cancer treatments and maximizing outcomes for patients with HCC Chair(s): Richard Finn, US	
18:30 - 18:35	Welcome and introduction R. Finn, UCLA - David Geffen School of Medicine, Los Angeles, US
18:35 - 18:50	Innovating to address unmet needs R. Finn 1 , P. Chow 2 , 1UCLA - David Geffen School of Medicine, Los Angeles, US, 2NCCS - National Cancer Centre Singapore, Singapore, SG
18:50 - 19:10	Current therapeutic approaches in HCC P. Chow 1 , M. Allaire 2 , 1NCCS - National Cancer Centre Singapore, Singapore, SG, 2Hopital Pitié Salpêtrière AP-HP, Paris, FR
19:10 - 19:30	The importance of surveillance and diagnosis A. Saborowski 1 , A. Yopp 2 , 1MHH - Medizinische Hochschule Hannover, Hannover, DE, 2UT Southwestern Medical Center, Dallas, US
19:30 - 19:40	Experiences from the clinic: a dynamic case study discussion R. Finn 1 , A. Yopp 2 , A. Saborowski 3 , M. Allaire 4 , P. Chow 5 , 1UCLA - David Geffen School of Medicine, Los Angeles, US, 2UT Southwestern Medical Center, Dallas, US, 3MHH - Medizinische Hochschule Hannover, Hannover, DE, 4Hopital Pitié Salpêtrière AP-HP, Paris, FR, 5NCCS - National Cancer Centre Singapore, Singapore, SG



<b>Educational Session - Burgos Auditorium - Hall 5</b>	
13:05 - 13:15	Evolving Standards: Maximizing Outcomes in Advanced HCC with Immunotherapy L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT
13:15 - 13:30	Crafting the Future: Emerging Multimodal Strategies for Embolization-Eligible HCC B. Sangro, Clinica Universidad de Navarra, Pamplona, ES
13:30 - 13:45	Raising the Bar: Optimizing Curative Opportunities in Early HCC S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK
13:45 - 14:00	Maximizing Potential: Integrating Immunotherapy into the Management of BTC A. Vogel, MHH - Medizinische Hochschule Hannover, Hannover, DE
14:00 - 14:20	The Art and Science of Immunotherapy in Clinical Practice: A Case-Based Discussion - B. Sangro 1, L. Rimassa 2, S. Chan 3, A. Vogel 4, 1 Clinica Universidad de Navarra, Pamplona, ES, 2 IRCCS Humanitas Research Hospital, Rozzano, IT, 3 The Chinese University of Hong Kong - Sino Building, Sha Tin, HK, 4MHH - Medizinische Hochschule Hannover, Hannover, DE
<b>Educational Session - Sevilla Auditorium - Hall 2</b>	
10:15 - 10:20	Management of adjuvant/neoadjuvant HCC in 2024 - Chair(s): Lorenza Rimassa, IT; Angela Lamarca, ES
10:15 - 10:20	Presentation of case/condition A. Saborowski, MHH - Medizinische Hochschule Hannover, Hannover, DE
10:20 - 10:40	Update on adjuvant treatment T. Meyer, UCL Cancer Institute - Paul O'Gorman Building, London, GB
10:40 - 11:00	How are locoregional therapies evolving in HCC? B. Sangro, Clinica Universidad de Navarra, Pamplona, ES
11:00 - 11:20	How to select first-line and what to do after progression to immunotherapy L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT
<b>Special session -Zaragoza Auditorium - CC5</b>	
08:30 - 10:00	Biomarkers in everyday clinical practice- Chair(s): Mila Petrova, BG; Gabor Liposits, DK
09:30 - 09:50	Biomarkers in daily practice R. Vidra, The Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, RO
<b>Special symposium Sevilla Auditorium - Hall 2</b>	
10:15 - 11:45	Management of oligometastatic gastroesophageal cancer. Chair(s): Trevor Leong, AU; Radka Obermannova, CZ
<b>Educational Session - Madrid Auditorium - Hall 2</b>	
10:15 - 11:45	Molecular characterisation and novel targeted therapies in gastroesophageal and pancreatic cancer Chair(s): Sarah Derks, NL; Rupert Langer, AT
<b>Educational Session - Bilbao Auditorium - Hall 2</b>	
10:15 - 11:45	Neoadjuvant treatment for colon cancer: Building upon the existing data Chair(s): Eva Angenete, SE; Myriam Chalabi, NL



14:45 - 16:15	Personalisation of surgical and systemic approaches in 2024: Optimizing cure and quality of life in gastroesophageal cancer Chair(s): Yelena Janjigian, US; Sheraz Markar, GB
<b>Scientific Congress highlights - Sevilla Auditorium - Hall 2</b>	
10:00 - 10:20	Gastrointestinal tumours, lower digestive -D. Arnold, Asklepios Klinik Altona - Hämatologie, internistische Onkologie, Palliativmedizin und Rheumatologie, Hamburg, DE
10:20 - 10:40	Gastrointestinal tumours, upper digestive S. Derks, VU University Medical Centre, Amsterdam, NL

**14.09.2024**

**Educational Session - Keynote Sessions - Sevilla Auditorium - Hall 2**

08:30 - 10:00	Type: Proffered Paper session Auditorium - Hall 2 Title: Proffered paper session 2: GI tumours, upper digestive  Chair(s): Filippo Pietrantonio, IT; Tania Fleitas, ES
10:45 - 11:30	Type: Challenge your Expert Pamplona Auditorium - Hall 3 Title: Young onset of colorectal cancer: What do we need to know   Chair(s): Irit Ben-Aharon, IL
14:00 - 14:20	Metastatic colorectal cancer: Changing paradigms and the relevance for patient care - R. Corcoran, MGH - Massachusetts General Hospital, Boston, US
14:00 - 14:20	Profiling the biology of CRC: Actionability and implementability R. Corcoran, MGH - Massachusetts General Hospital, Boston, US
14:20 - 14:40	Optimal sequencing of therapeutic strategies in immunogenic CRC T. André, Hopital Saint-Antoine, Paris, FR
14:40 - 15:00	Optimal sequencing of therapeutic strategies in molecularly-driven CRC L. Weiss, Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, AT
15:00 - 15:20	Optimal sequencing of therapeutic strategies in biomarker unselected MSS CRC C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

**Posters**

16:00 - 16:10	LBA38 - Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase 2/3 study (DUBHE-H-308)
16:10 - 16:20	LBA39 - Updated efficacy and safety data from <b>IMbrave050</b> : Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
16:55 - 17:05	LBA40 - Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
17:30 - 17:42	LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 <b>LEAP-012 Study</b>



09:20 - 09:25	965MO - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): expanded analyses from <b>CheckMate 9DW</b>
09:25 - 09:30	947MO - Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 <b>HIMALAYA study</b> of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
16:30 - 16:35	1722MO - Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
16:35 - 16:40	1723MO - Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: single-arm phase II study (AXAGIST) P. Rutkowski 1, A. Kli
08:40 - 08:50	LBA59 - Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - Final Results of the IKF-AIO-Moonlight trial
09:25 - 09:35	1401O - Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)

**15.09.2024**

**Poster Sessions - Barcelona Auditorium - Hall 2**

08:30 - 10:00	Type: Proffered Paper session Auditorium - Hall 2 Title: Proffered paper session 1: GI tumours, lower Chair(s): Jenny Seligmann, GB; Julien Taieb, FR
08:30 - 10:00	Type: EONS Industry Satellite Symposium Segovia Auditorium - Hall 7 Title: Roche - Integration of subcutaneous therapies in cancer care Chair(s): Matthew Fowler, GB
10:15 - 11:45	Type: Educational session Bilbao Auditorium - Hall 2 Title: Neoadjuvant treatment for colon cancer: Building upon the existing data Chair(s): Eva Angenete, SE; Myriam Chalabi, NL
10:15 - 11:45	Type: Special symposium Auditorium - Hall 2 Title: Management of oligometastatic gastroesophageal cancer Chair(s): Trevor Leong, AU; Radka Obermannova, CZ
12:00 - 13:30	Type: EONS Industry Satellite Symposium Ronda Auditorium - Hall 7 Title: BMS - Subcutaneous administration of immunotherapy in different care settings Chair(s): Lena Sharp, SE

**16.09.2024**

10:15 - 11:30	<b>Type: Multidisciplinary session Auditorium - Hall 2</b> Title: Management of adjuvant/neoadjuvant HCC in 2024 Chair(s): Lorenza Rimassa, IT; Angela Lamarca, ES
18:30 - 20:00	<b>Type: Industry Satellite Symposium - Roche - Alicante Auditorium - Hall 3</b>



	Pioneering GI cancer treatments and maximizing outcomes for patients with HCC Chair(s): Richard Finn, US
--	--

*M-BR-00016468 Setembro/2024*

*Este material, de cunho estritamente científico, destina-se exclusivamente a profissionais de saúde habilitados a prescrever ou dispensar medicamentos.*

*Material com objetivo educacional e não tem a finalidade de condicionar a prescrição, uso, promoção, venda, recomendação, indicação ou endosso de nenhum produto Roche ou qualquer concessão de benefício à Roche.*

*As condições de aprovação dos produtos citados diferem internacionalmente, recomenda-se que a bula local vigente seja consultada.*